multiple myeloma	is a	hematologic malignancy
multiple myeloma	is a	plasma cell neoplasm
multiple myeloma	produces	monoclonal protein
monoclonal protein	circulates in	serum
monoclonal protein	appears in	urine
M-spike	detected by	serum protein electrophoresis
M-spike	used for	disease monitoring
bone lesions	occur in	multiple myeloma
bone lesions	are	lytic
bone lesions	detected by	imaging
bone pain	is a	presenting symptom
anemia	is a	common abnormality
hypercalcemia	is a	common abnormality
renal failure	is a	complication
CRAB features	define	symptomatic myeloma
beta-2 microglobulin	is a	prognostic biomarker
albumin	is a	prognostic biomarker
LDH	is a	prognostic biomarker
bone marrow	shows	clonal plasma cells
bone marrow plasma cells	express	CD138
cytogenetics	reveals	t(4;14) translocation
t(4;14) translocation	associates with	poor prognosis
t(14;16) translocation	associates with	adverse prognosis
del(17p)	associates with	high-risk disease
R-ISS	classifies	disease stage
beta-2 microglobulin	level	correlates with	disease burden
albumin	level	correlates with	prognosis
LDH	level	correlates with	prognosis
serum free light chain assay	shows	abnormal kappa/lambda ratio
kappa/lambda ratio	abnormal in	light-chain myeloma
immunofixation electrophoresis	detects	monoclonal protein
bone marrow plasma cells	percentage	greater than 10%
bone marrow biopsy	used for	disease assessment
imaging	reveals	bone lesions
skeletal survey	detects	lytic lesions
MRI	assesses	bone marrow involvement
PET-CT	assesses	metabolic activity
autologous stem cell transplant	used for	eligible patients
high-dose chemotherapy	precedes	autologous transplant
VRd regimen	used for	induction therapy
VCD regimen	used for	induction therapy
lenalidomide	is a	IMiD
pomalidomide	is a	IMiD
bortezomib	is a	proteasome inhibitor
carfilzomib	is a	proteasome inhibitor
dexamethasone	is a	corticosteroid
cyclophosphamide	is a	alkylating agent
melphalan	is a	alkylating agent
thalidomide	is a	IMiD
daratumumab	targets	CD38
isatuximab	targets	CD38
selinexor	used for	relapsed disease
pomalidomide	used for	relapsed disease
carfilzomib	used for	relapsed disease
disease control	achieved with	combination therapy
autologous transplant	provides	progression-free survival
bisphosphonates	reduce	skeletal-related events
zoledronic acid	is a	bisphosphonate
pamidronate	is a	bisphosphonate
osteonecrosis of the jaw	is a	bisphosphonate complication
infections	are a	complication of multiple myeloma
IgG myeloma	is a	disease subtype
IgA myeloma	is a	disease subtype
light-chain myeloma	is a	disease subtype
non-secretory myeloma	is a	disease subtype
t(11;14) translocation	is a	prognostic marker
t(6;14) translocation	observed in	myeloma
del(13q)	is a	prognostic marker
complex karyotype	is a	poor prognostic factor
minimal residual disease	indicates	depth of response
response rate	measures	treatment effectiveness
complete response	is a	deep response
partial response	is a	response category
stable disease	is a	response category
relapse	occurs after	remission
bone resorption	increases with	myeloma activity
paraprotein	is a	monoclonal protein
renal involvement	indicates	disease severity
Bence Jones protein	is a	urinary light chain
urine protein electrophoresis	detects	M-protein in urine
serum protein electrophoresis	detects	M-spike in serum
bone marrow biopsy	confirms	clonal plasma cells
bone marrow biopsy	guides	prognosis
serum free light chains	monitor	clonal production
amyloidosis	may complicate	myeloma
daratumumab	improves	overall survival
lenalidomide maintenance	prolongs	progression-free survival
pomalidomide maintenance	prolongs	progression-free survival
disease progression	signals	treatment failure
staging	guides	treatment selection
hypercalcemia	defines	metabolic complication
calcium	level	relates to hypercalcemia
renal function	influences	drug selection
immunoglobulin levels	decrease with	therapy
Bence Jones protein	is a	urinary marker
urine electrophoresis	detects	M-protein in urine
serum electrophoresis	detects	M-spike in serum
bone marrow biopsy	confirms	clonal plasma cells
